Free Trial
NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

→ Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad)
Free CBST Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CBST stock logo

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

CBST Stock News Headlines

April 11, 2024 | bbc.co.uk
Key facts about Cubism
January 13, 2024 | seekingalpha.com
CBST:CA The Cannabist Company Holdings Inc.
May 4, 2024 | Stansberry Research (Ad)
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
May 16, 2023 | bbc.co.uk
What is Cubism?
April 7, 2023 | thestreet.com
Cubist Stock Hits New 52-Week High (CBST)
March 30, 2023 | thestreet.com
Cubist Rises On Unusually High Volume (CBST)
March 18, 2023 | thestreet.com
Tetraphase Antibiotic Nearing Key Tolerability Test
March 11, 2023 | benzinga.com
Cubist Raises $7M to Make dApp Development More Efficient, Secure, and Scalable
May 4, 2024 | Stansberry Research (Ad)
Gold Mania
Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).
March 4, 2023 | thestreet.com
Tetraphase: Another Good Investment In Hot Antibiotic Market
December 17, 2022 | thestreet.com
Cubist Pharmaceuticals (CBST) Stock Skyrockets Today on $8.4 Billion Merck Deal
See More Headlines
Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/21/2014
Today
5/04/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBST
CUSIP
22967810
CIK
912183
Web
www.cubist.com
Phone
+1-781-8608660
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

CBST Stock Analysis - Frequently Asked Questions

How were Cubist Pharmaceuticals' earnings last quarter?

Cubist Pharmaceuticals Inc (NASDAQ:CBST) posted its quarterly earnings results on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.54. The biopharmaceutical company had revenue of $309.20 million for the quarter, compared to analyst estimates of $305.50 million. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. During the same period last year, the company posted $0.41 earnings per share.

What other stocks do shareholders of Cubist Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Netflix (NFLX), Novavax (NVAX), (QIHU) (QIHU), Seagen (SGEN), Bausch Health Companies (BHC), Baidu (BIDU), Booking (BKNG) and BioMarin Pharmaceutical (BMRN).

This page (NASDAQ:CBST) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners
Biden to Launch “FedNOW” [Move Your Money Now]
Priority Gold
Elon to Transform U.S. Economy?
Porter & Company
Automatic Income (from home)
Awesomely, LLC
Could Your Accounts Be Frozen?
Allegiance Gold
Urgent Nvidia Warning
Altimetry
The asset beating inflation by 4x
Colonial Metals
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Have You Seen Elon’s New A.I. Device? (Picture Inside)
InvestorPlace